This was an extended Series A extension. The total round size increased to 23 million EUR. Remiges Ventures led the financing again, together with LifeCare Partners. Carma Fund joined as a new investor.
About Kupando
German medtech startup developing therapies to address urgent medical needs in cancer and infectious diseases using a dual TLR agonist platform that stimulates innate immunity.
Schönefeld, Germany
Read Company ProfileFrequently Asked Questions
What type of funding round did Kupando raise?
Kupando raised a series-a round.
How much did Kupando raise in its series-a?
Kupando raised $10,000,000 EUR in its series-a.
Who invested in Kupando's series-a?
The investors in Kupando's series-a are: Remiges Ventures, LifeCare Partners, Brandenburg Kapital, High-Tech Gruenderfonds, Ventura Biomed Investors, Carma Fund.
What type of investment was Kupando's series-a?
Kupando's series-a was a equity investment.
How will Kupando use the funds from its series-a?
Kupando plans to use the funds for: advance KUP101 into clinical trials for solid tumors, accelerate infectious disease programs.